For research use only. Not for therapeutic Use.
EC5026(CAT: I016866) is a first-in-class oral non-opioid small-molecule inhibitor of soluble epoxide hydrolase (sEH), under investigation for its potential in pain management and inflammatory conditions. By inhibiting sEH, it stabilizes epoxyeicosatrienoic acids (EETs), which are lipid mediators with anti-inflammatory and analgesic properties. EC5026 offers a novel mechanism of action, making it a promising candidate for addressing chronic pain and inflammation without the risks associated with opioid-based therapies. This compound is a valuable tool for studying the role of sEH in physiological and pathological processes and for advancing non-opioid therapeutic strategies in pain and inflammation research.
| Catalog Number | I016866 |
| CAS Number | 1809885-32-2 |
| Molecular Formula | C₁₈H₂₃F₄N₃O₃ |
| Purity | ≥95% |
| Target | Epoxide Hydrolase |
| IUPAC Name | 1-[3-fluoro-4-(trifluoromethoxy)phenyl]-3-[1-[(2S)-2-methylbutanoyl]piperidin-4-yl]urea |
| InChI | InChI=1S/C18H23F4N3O3/c1-3-11(2)16(26)25-8-6-12(7-9-25)23-17(27)24-13-4-5-15(14(19)10-13)28-18(20,21)22/h4-5,10-12H,3,6-9H2,1-2H3,(H2,23,24,27)/t11-/m0/s1 |
| InChIKey | LHRXHTKENPCGSZ-NSHDSACASA-N |
| SMILES | CC[C@H](C)C(=O)N1CCC(CC1)NC(=O)NC2=CC(=C(C=C2)OC(F)(F)F)F |
